Recurrent Clostridium Difficile Infection — Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
Citation(s)
A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study